CRISPR Therapeutics (CRSP)

Executive Summary

CRISPR Therapeutics (CRSP) is a leading gene-editing company with the first approved CRISPR-based therapy, CASGEVY (exagamglogene autotemcel), for sickle cell disease and transfusion-dependent beta thalassemia. Co-developed with Vertex, CASGEVY has launched in key markets, and the company is focused on expanding its label and manufacturing capacity. Beyond hemoglobinopathies, CRISPR is advancing an allogeneic CAR-T pipeline targeting B-cell malignancies (CTX112) and solid tumors (CTX131), and has entered the autoimmune space with CTX112 for systemic lupus erythematosus. Recent clinical data have shown durable responses in B-cell lymphoma, and the lupus program is enrolling patients. Financially, the company benefits from CASGEVY royalties and a strong balance sheet, but ongoing R&D costs keep it pre-profitable. Key risks include competition from other gene therapies and potential manufacturing hurdles. However, CRISPR's platform versatility and first-mover advantage position it as a cornerstone of genetic medicine. The stock has significant upside if pipeline programs deliver, but near-term volatility is expected as the market prices in launch execution and catalyst timelines.

Upcoming Catalysts (preview)

• Q3 2026Exa-cel label expansion into additional patient populations (e.g., younger children or other hemoglobinopathies)70% success
• Q2 2026CTX112 Phase 1 data readout in systemic lupus erythematosus (SLE)40% success
• H2 2026CTX131 initial efficacy and safety data in T-cell lymphoma and solid tumors50% success